| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | 0.035 | 0.6 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |